Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 104 participants.

Also called NCT04189848

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 104 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04189848
Other papers using this trial's data
  • Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects Diabetes, obesity & metabolism, 2021-06 DOI, PubMed 33591618, PMC8251561 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04189848. Randomized; quadruple masking; primary purpose treatment. Start 2019-12-03 (actual); primary completion 2020-01-29 (actual). Results posted on 2021-02-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc
Condition
Healthy Volunteers
Condition
Diabetes Mellitus, Type 2
Condition
Overweight
Condition
Obesity
Intervention (Drug)
Semaglutide
Intervention (Drug)
Dulaglutide
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct04189848
Content hash
22da4dfe332a08a06c27474ad06841e470d5b6fa1e9619cef0aa68070b55450c